Squarepoint Ops LLC Decreases Stock Holdings in Medpace Holdings, Inc. $MEDP

Squarepoint Ops LLC reduced its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 68.4% in the second quarter, HoldingsChannel reports. The institutional investor owned 18,370 shares of the company’s stock after selling 39,705 shares during the quarter. Squarepoint Ops LLC’s holdings in Medpace were worth $9,729,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the company. Baird Financial Group Inc. grew its holdings in Medpace by 78.9% in the 2nd quarter. Baird Financial Group Inc. now owns 1,145 shares of the company’s stock worth $606,000 after acquiring an additional 505 shares during the last quarter. Arizona State Retirement System raised its stake in shares of Medpace by 2.1% during the second quarter. Arizona State Retirement System now owns 6,304 shares of the company’s stock valued at $3,339,000 after acquiring an additional 131 shares during the last quarter. West Family Investments Inc. purchased a new stake in shares of Medpace during the second quarter worth about $317,000. Nykredit A S purchased a new stake in shares of Medpace during the second quarter worth about $356,000. Finally, Corient Private Wealth LP grew its stake in shares of Medpace by 291.4% in the second quarter. Corient Private Wealth LP now owns 6,314 shares of the company’s stock worth $3,344,000 after purchasing an additional 4,701 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Transactions at Medpace

In other Medpace news, CEO August J. Troendle sold 650 shares of the firm’s stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $620.27, for a total transaction of $403,175.50. Following the completion of the transaction, the chief executive officer owned 539,894 shares of the company’s stock, valued at approximately $334,880,051.38. This trade represents a 0.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Robert O. Kraft sold 3,858 shares of the business’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $617.81, for a total transaction of $2,383,510.98. Following the sale, the director owned 955 shares in the company, valued at approximately $590,008.55. This trade represents a 80.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 134,471 shares of company stock valued at $82,151,311. Company insiders own 20.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Truist Financial boosted their price target on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a report on Friday, July 24th. Leerink Partners set a $620.00 price objective on Medpace in a research report on Thursday, July 23rd. TD Cowen boosted their target price on Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $535.00 target price on shares of Medpace in a report on Thursday, July 23rd. Finally, BMO Capital Markets raised their price target on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research note on Friday, July 24th. Three analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, Medpace presently has a consensus rating of “Hold” and an average price target of $595.20.

Medpace Price Performance

MEDP stock opened at $583.16 on Friday. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90. The firm has a 50-day moving average of $578.40 and a 200 day moving average of $504.09. The company has a market cap of $16.28 billion, a P/E ratio of 34.18, a PEG ratio of 2.62 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. During the same period in the previous year, the firm posted $3.10 EPS. The business’s revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities research analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.